MedTrace Logo

Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia

NCT03651102 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 654

Last updated 2022-03-25

No results posted yet for this study

Summary

Thalidomide is known to have hypnosedative, immuno-modulatory and anti-angiogenic effects. The drug is widely used in several neoplastic disorders (e.g. multiple myeloma and malignant melanoma), inflammatory conditions (e.g. Crohn's disease) and skin disorders (e.g. leprosy). Thalidomide has been successfully used in adult thalassemia patients. The current study explores its role in transfusion-dependent thalassemia patients.

Conditions

Interventions

DRUG

Thalidomide and Hydroxyurea

Dosage: Thalidomide 1-4mg/kg/day, Hydroxyurea 10-20mg/kg/day

Sponsors & Collaborators

  • University of Peshawar

    collaborator OTHER

  • Blood Diseases Clinic

    lead OTHER

Principal Investigators

  • Muhammad Tariq M Khan, MBBS, PhD · Blood Diseases Clinic

  • Zahid Ali, PharmD, MPhil · Department of Pharmacy, University of Peshawar

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2021-11-30
Completion
2022-03-01

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03651102 on ClinicalTrials.gov